GlassScriptPhysician profile
Julia C Collins
NPI 1326625781
$20,807.34
in general payments reported to CMS, 2019-2025
25 companies · $19K in 2025
The $19K reported for 2025 was more than what 93% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $384 · 2024: $978 · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $19K · Food and Beverage: $1,716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $19,091.00 |
| Food and Beverage | $1,716.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $10,000.00 | 2025 | Vercise |
| Abbott Laboratories | $9,091.00 | 2025 | Infinity |
| Neurocrine Biosciences, INC. | $397.41 | 2024 | Ingrezza |
| Emd Serono, INC. | $347.57 | 2023-2025 | Mavenclad, Mavenclad |
| Medtronic, INC. | $169.46 | 2025 | Solitaire X |
| Ucb, INC. | $103.60 | 2023-2025 | Briviact, Rystiggo |
| Genentech USA, INC. | $64.00 | 2023-2024 | Enspryng, Ocrevus, Tnkase |
| Immedica Pharma US, INC. | $63.70 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.15 | 2024 | Hyqvia |
| Lilly USA, LLC | $55.97 | 2024 | Amyvid, Kisunla |
| Abbvie INC. | $54.31 | 2023-2025 | Botox |
| Biogen, INC. | $50.83 | 2023-2024 | Tysabri, Vumerity |
| Ipsen Biopharmaceuticals, INC | $44.66 | 2024 | Dysport |
| Eisai INC. | $43.75 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $40.05 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $37.60 | 2023-2024 | Ultomiris |
| Lundbeck LLC | $29.88 | 2024 | Vyepti |
| Livanova USA, INC. | $26.20 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
| Ani Pharmaceuticals, INC. | $26.11 | 2025 | Purified Cortrophin Gel |
| Otsuka America Pharmaceutical, INC. | $18.88 | 2025 | Rexulti |
| Octapharma USA, INC. | $18.16 | 2024 | Panzyga |
| Sandoz INC. | $17.77 | 2024 | |
| Amneal Pharmaceuticals LLC | $17.70 | 2023 | Rytary |
| Pfizer INC. | $15.48 | 2023 | |
| Argenx US, INC. | $14.10 | 2024 | Vyvgart Hytrulo, Vyvgart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.